Filana Therapeutics appointed Jill M. Quigley to its Board of Directors as a Class I director, effective November 8, 2026. Ms. Quigley brings over 20 years of biopharma leadership experience, including previous CEO and COO roles at Genuiti Therapeutics and Passage Bio. Her appointment is intended to support the company as it prepares for a Phase 2a clinical study of simufilam in TSC-related epilepsy.
Filana Therapeutics reported a net loss of $10.7 million for the third quarter of 2026, with a significant reduction in nine-month operating expenses compared to the prior year. The company received a Nasdaq deficiency notice regarding its share price but maintains a cash position of $78.2 million, which management believes is sufficient for at least the next 12 months.
Filana Therapeutics reported Q3 2026 financial results, including a net loss of $10.7 million and a cash balance of $47.0 million. The company announced that patient screening for its Phase 2a study of simufilam in TSC-related epilepsy is expected to begin by Q1 2027 following the recent lifting of an FDA clinical hold.
“Simufilam has the potential to make a meaningful difference for patients with TSC-related epilepsy. We began working toward activating clinical study sites as soon as FDA lifted the clinical hold in September. Patient screening is expected to begin by the first quarter of 2027.”
The U.S. Court of Appeals for the Fifth Circuit vacated a lower court's order that had granted class certification in a securities class action against Filana Therapeutics. The appellate court ruled that the district court misapplied legal standards regarding market efficiency and 'meme-stock' dynamics, remanding the case for further proceedings.
Counterparty
U.S. District Court for the Western District of Texas